Segui
Guillaume Lingas
Guillaume Lingas
Affiliazione sconosciuta
Email verificata su inserm.fr
Titolo
Citata da
Citata da
Anno
Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths
P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ...
Science immunology 6 (62), eabl4340, 2021
4382021
X-linked recessive TLR7 deficiency in~ 1% of men under 60 years old with life-threatening COVID-19
T Asano, B Boisson, F Onodi, D Matuozzo, M Moncada-Velez, ...
Science immunology 6 (62), eabl4348, 2021
3272021
Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort
N Néant, G Lingas, Q Le Hingrat, J Ghosn, I Engelmann, Q Lepiller, ...
Proceedings of the National Academy of Sciences 118 (8), e2017962118, 2021
2002021
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
JS Driouich, M Cochin, G Lingas, G Moureau, F Touret, PR Petit, ...
Nature communications 12 (1), 1735, 2021
1332021
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
J Manry, P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, ...
Proceedings of the National Academy of Sciences 119 (21), 2022
1272022
Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives
Q Le Hingrat, B Visseaux, C Laouenan, S Tubiana, L Bouadma, ...
Clinical Microbiology and Infection 27 (5), 789. e1-789. e5, 2021
642021
The value of open-source clinical science in pandemic response: lessons from ISARIC
A Abbas, SA Abdukahil, NN Abdulkadir, R Abe, L Abel, L Absil, S Acharya, ...
The Lancet infectious diseases 21 (12), 1623-1624, 2021
322021
Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin
G Lingas, K Rosenke, D Safronetz, J Guedj
PLoS Computational Biology 17 (1), e1008535, 2021
282021
ISARIC-COVID-19 dataset: a prospective, standardized, global dataset of patients hospitalized with COVID-19
M Etienne, N Ettalhaoui, AG Everding, M Evers, I Fabre, M Fabre, ...
Scientific data 9 (1), 454, 2022
272022
Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial
G Lingas, N Néant, A Gaymard, D Belhadi, G Peytavin, M Hites, T Staub, ...
Journal of Antimicrobial Chemotherapy 77 (5), 1404-1412, 2022
272022
French COVID Cohort Investigators and French Cohort Study groups. Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French …
N Néant, G Lingas, Q Le Hingrat, J Ghosn, I Engelmann, Q Lepiller, ...
Proc. Natl. Acad. Sci. USA 118 (8), e2017962118, 2021
212021
Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates
R Marlin, D Desjardins, V Contreras, G Lingas, C Solas, P Roques, ...
Nature Communications 13 (1), 5108, 2022
162022
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model. Nat. Commun. 12, 1735
JS Driouich, M Cochin, G Lingas, G Moureau, F Touret, PR Petit, ...
82021
Survival of SARS-CoV-2 on non-porous materials in an experimental setting representative of fomites
L Bonil, G Lingas, D Coupeau, JC Lucet, J Guedj, B Visseaux, B Muylkens
Coatings 11 (4), 371, 2021
72021
Favipiravir and severe acute respiratory syndrome coronavirus 2 in hamster model
JS Driouich, M Cochin, G Lingas, G Moureau, F Touret, PR Petit, ...
bioRxiv, 2020.07. 07.191775, 2020
72020
Association of country income level with the characteristics and outcomes of critically ill patients hospitalized with acute kidney injury and COVID-19
M Wainstein, N Spyrison, D Dai, M Ghadimi, JS Chávez-Iñiguez, ...
Kidney international reports 8 (8), 1514-1530, 2023
62023
T Cell immunogenicity, gene expression profile, and safety of four heterologous prime-boost combinations of HIV vaccine candidates in healthy volunteers: Results of the …
L Richert, JD Lelièvre, C Lacabaratz, L Hardel, H Hocini, A Wiedemann, ...
The Journal of Immunology 208 (12), 2663-2674, 2022
62022
Symptom‐based case definitions for COVID‐19: Time and geographical variations for detection at hospital admission among 260,000 patients
J Baruch, A Rojek, C Kartsonaki, BKT Vijayaraghavan, BP Gonçalves, ...
Influenza and other respiratory viruses 16 (6), 1040-1050, 2022
52022
Chronic use of renin‐angiotensin‐aldosterone system blockers and mortality in COVID‐19: A multicenter prospective cohort and literature review
N Gault, M Esposito‐Farèse, M Revest, J Inamo, A Cabie, É Polard, ...
Fundamental & Clinical Pharmacology 35 (6), 1141-1158, 2021
32021
Association between SARS‐CoV‐2 viral kinetics and clinical score evolution in hospitalized patients
N Néant, G Lingas, A Gaymard, D Belhadi, M Hites, T Staub, R Greil, ...
CPT: Pharmacometrics & Systems Pharmacology 12 (12), 2027-2037, 2023
22023
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20